See the latest news and media coverage for Ziccum. We track all announcements, press releases, and industry mentions in real time, all in one place.
Mass transfer drying technology for biologics
ziccum.comLast updated
In short: Ziccum filed for bankruptcy at Lund District Court following failed financing attempts and insufficient funding from GCF.
The board justifies the decision with insufficient capital from recently completed preferential share issues and rejected loans, which forces the company to shut down development of LaminarPace technology.
The company allocates 4.7 million shares to Global Corporate Finance for roughly 2.2 million Swedish kronor to fund operations through 2025.
The board decides to apply at Lund District Court due to insufficient financing after failed emission and denied financing from GCF.
The board calls third investment tranche of 4,698,588 shares at SEK 0.47, raising SEK 2.2M amid financial challenges post disappointing rights issue. Dilution is 15.91%.
Ziccum has decided on two new share issues, one of which is directed to Global Corporate Finance, GCF, and the other a rights issue. The directed new share issue amounts to...
Ziccum intends to resolve on a rights issue of approximately SEK 30 million and raises a bridge loan On October 10, The Board of Directors...
Close Agenda: Quadruple witching and more interest rate decisions. Get an overview of the most important highlights ahead of Friday December 17 Ziccum, which develops new formulations of vaccines, confirms...
My account Log in {{ truncateString(window.visitor.corporateClient.name, 12) }}{{ truncateString(window.visitor.corporateClient.name, 20) }} {{ truncateString ...
Track Ziccum and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Ziccum and other trending companies.